SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy
Many patients will continue to face higher out-of-pocket costs or rely on the company’s cash-pay option without broader commercial coverage. The company lowered its expected operating expenses for 2026 to $248 million, reflecting tighter cost controls. It also reaffirmed its target of reaching cash flow break-even in 2027. Management highlighted that demand for neffy continues … Read more